What is the price target for MLND stock?
0 analysts have analysed MLND and the average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06.
Millendo Therapeutics Inc (MLND) Forecast, Price Target & Analyst Ratings
NASDAQ:MLND
Current stock price
1.06
-0.06 (-5.36%)
At close:
1.06
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Millendo Therapeutics Inc (MLND).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q2 / 2021
- EPS Estimate
- -$0.37
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$2.04
Upside
+ 92.45%
From current price of $1.06 to mean target of $2.04, Based on 0 analyst forecasts
Low
$2.02
Median
$2.04
High
$2.10
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
0 Wall Street analysts provided a forecast for the next 12 months for MLND. The average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
0.00%
MLND is currently not analyzed by any analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q2 / 2021
- EPS Estimate
- -$0.37
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 34.43%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A 104.27% | N/A -37.41% | N/A -91.48% | N/A -100.00% | N/A | N/A | N/A | N/A | N/A | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -40.65 | -36.75 9.59% | -20.85 43.27% | N/A 87.82% | -3.26 -28.36% | -1.94 40.49% | N/A 33.23% | N/A 62.99% | N/A 48.74% | N/A 47.72% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 21 | Q3 / 21 | Q4 / 21 | Q4 / 22 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 34.43% | -0.30 13.00% | -0.31 21.54% | -1.44 -369.87% |
| Revenue Q2Q % growth | 2.084M | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | N/A | N/A | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.27%
EPS Next 5 Year
17.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
Millendo Therapeutics Inc / MLND Forecast FAQ
What are the consensus estimates for MLND stock next earnings?
The consensus EPS estimate for the next earnings of Millendo Therapeutics Inc (MLND) is -0.37 null and the consensus revenue estimate is 0 null.